Response to Comments: MolDX: Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer

This document is an administrative Response to Comments for MolDX Inivata/InVisionFirst liquid biopsy policy DL37870 and does not contain clinical coverage criteria. It records the comment period (2018-10-01 to 2018-11-15), the notice period (2019-02-21 to 2019-04-07), and that the LCD became final on 2019-04-08. Manual review of the referenced LCD (DL37870) or the final LCD is required to extract specific clinical indications, limitations, documentation, and frequency rules for coverage.

"No clinical coverage criteria are provided in this document; it records administrative timeline information for the Response to Comments to MolDX LCD DL37870: comment period 2018-10-01 to 2018-11-1..."

Sign up to see full coverage criteria, indications, and limitations.